AUTHORS
Reed Friend, MD, Andrew J. Portuguese, MD2, Cindy Varga, MD,BSc3, Christopher J. Ferreri, MD4, Jack Khouri, MD5, Lekha Mikkilineni, MD, MA6, Ariel Grajales-Cruz, MD7, Omar Puglianini, MD8, Rachid Baz, MD9, Hien Liu, MD10, Mikhaila Rice, PharmD11, Shahzad Raza, MD12, Faiz Anwer, MD13, Nilesh Kalariya, APRN, PhD14, Krina Patel Jr, MD, MSc15, Sharlene Dong, MD, MS16, Sarvari V. Yellapragada, MD17, Poy Theprungsirikul, MD18, Shonali Midha, MD19, Omar Nadeem, MD20, Danai Dima, MD21, Rahul Banerjee, MD22, Masooma Shifa Rana, MBBS23, Ricardo Daniel Parrondo, MD24, Saurabh Chhabra, MD, MBBS25, Yi Lin Jr, MD, PhD26, Saurabh Zanwar, MBBS, MD27, Aimaz Afrough, MD28, Samer Al Hadidi, MD29, Larry D Anderson Jr, MD, PhD30, James A Davis, PharmD, BCOP31, Anthony Dominick32, Kelley Julian, PharmD, BCOP33, Doug W. Sborov, MD, MS34, Francesca Cottini, MD35, Timothy O'Brien, MD36, Sarah Lee Jr37, Darren Pan, MD38, Ajai Chari, MD39, Binoy Yohannan, MD40, Noa Biran, MD41, Erin Eberwein42, Ana Maria Avila Rodriguez, MD43, Shebli Atrash, MD44, Manisha Bhutani, MD45, Nisha Joseph, MD46, Alissa Visram, MD, MPH47, Megan M Herr, PhD48, Ashley Rosko, MD49, Surbhi Sidana, MD50, Doris K. Hansen, MD51, Hira Mian, MD52, Peter Voorhees, MD53, Nadine Abdallah I, MD54
AFFILIATIONS
1 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
2 University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
4 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
5 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
6 Stanford University School of Medicine, Stanford, California, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Charlotte, Florida, United States
8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
11 Taussig Cancer Center Cleveland Clinic, Cleveland, Ohio, United States
12 Taussig Cancer Center Cleveland Clinic, Cleveland, Ohio, United States
13 Taussig Cancer Center Cleveland Clinic, Cleveland, Ohio, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Division of Myeloma, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
21 Fred Hutchinson Cancer Center, Seattle, Washington, United States
22 Fred Hutchinson Cancer Center, Seattle, Washington, United States
23 University of Nebraska Medical Center, Omaha, Nebraska, United States
24 Mayo Clinic-Florida, Jacksonville, Florida, United States
25 Mayo Clinic, Phoenix, Florida, United States
26 Mayo Clinic, Rochester, Minnesota, United States
27 Mayo Clinic, Rochester, Minnesota, United States
28 UT Southwestern Medical Center, Dallas, Texas, United States
29 UT Southwestern Medical Center, Dallas, Dallas, Texas, United States
30 UT Southwestern Medical Center, Dallas, Texas, United States
31 Medical University of South Carolina, Charleston, South Carolina, United States
32 Medical University of South Carolina, Charleston, South Carolina, United States
33 Huntsman Cancer Institute, Salt Lake City, Utah, United States
34 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
35 The Ohio State University, Columbus, Ohio, United States
36 Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
37 City of Hope, Duarte, California, United States
38 University of California San Francisco, San Francisco, California, United States
39 University of California San Francisco, San Francisco, California, United States
40 University of Minnesota, Minneapolis, Minnesota, United States
41 Hackensack University Medical Center, Hackensack, New Jersey, United States
42 Duke University School of Medicine, Durham, North Carolina, United States
43 University of Illinois Chicago, Chicago, Illinois, United States
44 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
45 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
46 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
47 Juravinski Cancer Center at McMaster University, Hamilton, Hamilton, Canada
48 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
49 The Ohio State University, Columbus, Ohio, United States
50 Stanford University School of Medicine, Stanford, California, United States
51 Moffitt Cancer Center, Tampa, Florida, United States
52 McMaster University, Hamilton, Canada
53 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
54 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background: Bispecific antibodies (BsAbs) are reshaping treatment for relapsed/refractory multiple myeloma (RRMM). Older adults are underrepresented in BsAb trials, and real-world data remain limited.
Methods: We conducted a multicenter retrospective study across 22 US MM Immunotherapy Consortium sites comparing older (≥70 years [yo]) and younger patients (pts) with RRMM treated with BCMA- or GPRC5D-directed BsAbs. Age 70 was chosen as it approximated the cohort median (69 years). For pts receiving multiple BsAbs, the first for each target was analyzed; bridging BsAbs were excluded. Multivariable models adjusted for ECOG performance status, sex, prior lines of therapy (LOT), ≥1 high-risk cytogenetic abnormality (HRCA), extramedullary disease (EMD), prior autologous stem cell transplantation (ASCT), prior CAR-T, prior BCMA/GPRC5D-directed therapy, and BsAb class. HRCA was defined as del(17p), t(4;14), t(14;16), or gain/amp 1q.
Results: Among 1,812 pts (age range 30-95 yo), 858 (47%) were ≥70 yo and 954 (53%) were <70 yo. BsAb exposure included teclistamab in 970 pts (54%), talquetamab in 587 pts (32%), elranatamab in 237 pts (13%), and linvoseltamab in 18 pts (1%). Median follow-up was 19.2 months. Older pts were more often female (52% vs 46%) and had ECOG ≥2 (29% vs 22%) but fewer adverse features, including prior LOT (median, 5 vs 6), EMD (14% vs 22%), ≥1 HRCA (61% vs 69%), penta-refractory disease (38% vs 44%), prior CAR-T (29% vs 46%), and prior BCMA-directed therapy (41% vs 58%). Median baseline ferritin and CRP were lower in older pts (234 vs 434 ng/mL; 2 vs 4 mg/L; both p<0.001), whereas albumin was similar.
Older pts had higher response rates, including ≥PR (66% vs 59%; p<0.001), ≥VGPR (56% vs 46%; p<0.001), and CR/sCR (36% vs 29%; p=0.002). In multivariable analysis, age ≥70 was independently associated with ≥PR (OR, 1.47; 95% CI, 1.15-1.88; p=0.002) and ≥VGPR (OR, 1.50; 95% CI, 1.19-1.88; p<0.001).
Cytokine release syndrome (CRS) occurred less often in older pts (46% vs 53%, p=0.001). Despite more prophylactic (ppx) tocilizumab (toci) use in older pts (12% vs 9.1%; p=0.026), age ≥70 remained independently associated with lower odds of grade ≥1 CRS after adjustment for ppx toci (OR, 0.75; 95% CI, 0.60-0.94; p=0.01). Rates of grade ≥2 CRS (14% vs 16%; p=0.33) and grade ≥3 CRS (1.9% vs 2.3%; p=0.52) were similar. Older pts had more all-grade (17% vs 11%; p<0.001) and grade ≥2 immune effector cell-associated neurotoxicity syndrome (ICANS) (8.1% vs 5.0%; p=0.007), while grade ≥3 ICANS was similar between groups (2.7% vs 2.4%; p=0.72). Age ≥70 was independently associated with higher odds of grade ≥1 ICANS (OR, 1.48; 95% CI, 1.07-2.03; p=0.02). Rates of any (rate ratio [RR] 1.21; 95% CI, 0.99-1.48; p=0.06), and severe infection (RR 1.20; 95% CI, 0.80-1.81; p=0.38) were similar by age. IVIG use was similar (68% vs 67%; p=0.70).
First-cycle treatment delays were similar by age (32% in both groups), and infection- or cytopenia-related delays did not differ. Older pts had more ICANS-related delays (6.7% vs 3.8%; p=0.025), while CRS-related delays were numerically less frequent (11% vs 15%; p=0.089).
Treatment discontinuation was less common in older pts (70% vs 76%; p=0.005), and time to discontinuation was longer (median, 3.6 vs 2.7 months; p=0.018). Older pts were less likely to discontinue because of progression (35% vs 51%) but more likely to discontinue because of toxicity (11% vs 6%), death (8.4% vs 6.1%), or other non-progression causes. Non-relapse mortality (NRM) was higher among older pts (12-month: 11.3% vs 6.1%; 24-month: 16.3% vs 7.4%; p<0.001). At 12 mo, infection-related mortality was higher among pts aged ≥70 vs < 70 yrs (2.8% vs 1.4%; Gray’s p=0.005).
Median PFS was longer in pts aged ≥70 vs <70 yrs (12.4 vs 6.6 months; adjusted HR, 0.77; 95% CI, 0.67–0.89; p<0.001), whereas median OS was similar (25.4 vs 20.2 months; adjusted HR, 0.88; 95% CI, 0.74–1.04; p=0.13). Results were consistent using an age ≥75 cutoff.
Conclusion: In this large real-world study, older pts selected for BsAb therapy achieved higher response rates and improved PFS compared with younger patients, with no difference in OS. Although older pts experienced more ICANS, toxicity-related discontinuation, and NRM, these risks appear manageable with infection ppx, supportive care and geriatric informed selection. These findings support that chronologic age alone should not preclude BsAb use in RRMM.
DISCLOSURES
Reed Friend, MD: BMS - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)